

Reena S Cecchini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6738471/publications.pdf>

Version: 2024-02-01

31
papers

5,020
citations

331670

21
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

5076
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial<SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 2727.	7.4	1,499
2	Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 2005, 97, 1652-1662.	6.3	1,192
3	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research, 2010, 3, 696-706.	1.5	560
4	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet, The, 2019, 394, 2155-2164.	13.7	319
5	NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology, 2020, 38, 444-453.	1.6	234
6	Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07. Journal of Clinical Oncology, 2007, 25, 2205-2211.	1.6	206
7	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 849-856.	13.7	148
8	Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial. Journal of Clinical Oncology, 2011, 29, 1110-1116.	1.6	108
9	Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Research and Treatment, 2009, 113, 315-320.	2.5	93
10	Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials. Cancer Prevention Research, 2012, 5, 583-592.	1.5	93
11	Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer, 2012, 118, 5614-5622.	4.1	76
12	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 857-865.	13.7	67
13	Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06. Journal of Clinical Oncology, 2007, 25, 424-430.	1.6	60
14	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology, 2017, 35, 3942-3948.	1.6	55
15	25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Research and Treatment, 2012, 133, 1077-1088.	2.5	51
16	Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). American Journal of Obstetrics and Gynecology, 2011, 205, 535.e1-535.e5.	1.3	48
17	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Research and Treatment, 2020, 179, 161-171.	2.5	39
18	Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 51-59.	2.5	33

#	ARTICLE	IF	CITATIONS
19	The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer. Recent Results in Cancer Research, 2009, 181, 113-119.	1.8	29
20	An Association Between Postoperative Radiotherapy for Primary Breast Cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) Studies and the Subsequent Appearance of Pleural Mesothelioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 294-296.	1.3	25
21	Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR). Cancer Prevention Research, 2012, 5, 1321-1329.	1.5	23
22	Adolescentsâ€™ Experiences Using the Contraceptive Patch versus Pills. Journal of Pediatric and Adolescent Gynecology, 2011, 24, 197-203.	0.7	19
23	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. Journal of Clinical Oncology, 2015, 33, LBA500-LBA500.	1.6	12
24	Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. Contemporary Clinical Trials Communications, 2018, 10, 100-104.	1.1	8
25	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Journal of Clinical Oncology, 2021, 39, 3800-3812.	1.6	6
26	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 2021, 113, 1105-1108.	6.3	5
27	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.. Journal of Clinical Oncology, 2015, 33, 1500-1500.	1.6	5
28	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. Npj Breast Cancer, 2021, 7, 55.	5.2	4
29	Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.. Journal of Clinical Oncology, 2018, 36, 10066-10066.	1.6	2
30	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. Journal of Clinical Oncology, 2015, 33, LBA500-LBA500.	1.6	0
31	Abstract P1-07-04: Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52. Cancer Research, 2022, 82, P1-07-04-P1-07-04.	0.9	0